Pandemic drugs at pandemic speed: infrastructure for accelerating COVID-19 drug discovery with hybrid machine learning- and physics-based simulations on high-performance computers

Mostrar otras versiones (1)

The race to meet the challenges of the global pandemic has served as a reminder that the existing drug discovery process is expensive, inefficient and slow. There is a major bottleneck screening the vast number of potential small molecules to shortlist lead compounds for antiviral drug development....

Descripción completa

Detalles Bibliográficos
Autores principales: Bhati, Agastya P., Wan, Shunzhou, Alfè, Dario, Clyde, Austin R., Bode, Mathis, Tan, Li, Titov, Mikhail, Merzky, Andre, Turilli, Matteo, Jha, Shantenu, Highfield, Roger R., Rocchia, Walter, Scafuri, Nicola, Succi, Sauro, Kranzlmüller, Dieter, Mathias, Gerald, Wifling, David, Donon, Yann, Di Meglio, Alberto, Vallecorsa, Sofia, Ma, Heng, Trifan, Anda, Ramanathan, Arvind, Brettin, Tom, Partin, Alexander, Xia, Fangfang, Duan, Xiaotan, Stevens, Rick, Coveney, Peter V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504892/
https://www.ncbi.nlm.nih.gov/pubmed/34956592
http://dx.doi.org/10.1098/rsfs.2021.0018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504892/
https://www.ncbi.nlm.nih.gov/pubmed/34956592
http://dx.doi.org/10.1098/rsfs.2021.0018

Ejemplares similares